Chiesi Group accelerates sustainable growth in H1 2025, delivering strong financial results and reaffirming commitment to Shared Value
16 Settembre 2025
Chiesi Global Rare Diseases receives Swissmedic approval for FILSUVEZ® topical gel for the treatment of epidermolysis bullosa
11 Agosto 2025
Chiesi Group and Serna Bio announce strategic collaboration to discover and develop RNA-targeted small molecules for respiratory diseases
24 Luglio 2025
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability
16 Aprile 2025
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
26 Marzo 2025
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth
29 Gennaio 2025
Great Place To Work and Fortune Name Chiesi Group No. 23 in 2024 World’s Best Workplaces™ List
14 Novembre 2024
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
